Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Forest Laboratories/Replidyne's faropenem medoxomil, the first oral penem expected to enter the U.S. market, receives high marks from pediatricians on clinical advantages -- more so than primary care physicians (PCPs). The new PhysicianForum report entitled Antibiotics: Reaction of PCPs, Pediatricians, and Managed Care to Major Patent Expiries and New Products finds that 39% of PCPs and 63% of pediatricians perceive faropenem medoxomil to be an antibiotic with major clinical advantages. However, HMOs don't feel the same.

"In contrast to physicians, more than 50% of HMO pharmacy directors believe faropenem medoxomil will be a 'me-too' beta-lactam without any major advantages over other agents already on the market," said Sylvia Eash, Ph.D., analyst at Decision Resources. "Therefore, the product will face significant hurdles from managed care: nearly 70% of HMO pharmacy directors say they will place it on a higher tier once the drug enters the market."

The report also finds that Pfizer's branding for Z-PAK has made it the most requested antibiotic product on the market -- though managed care is aggressively controlling its use following azithromycin's patent expiry. More than 60% of PCPs and pediatricians cite Zithromax Z-PAK as the most patient-requested brand antibiotic.

Dr. Eash continued, "Pfizer's effective positioning of Z-PAK serves as an example for new entrants. Although physicians report that relatively few patients request specific antibiotics by brand, Pfizer's effective marketing of Z-PAK makes it, by far, the most requested antibiotic product."

About PhysicianForum

PhysicianForum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

Antibiotics: Reaction of PCPs, Pediatricians, and Managed Care to Major Patent Expiries and New Products is based on a U.S. survey of 20 managed care pharmacy and medical directors, 40 pediatricians, and 101 primary care physicians. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic, and scientific factors.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Drugs from Astrazeneca/Renovis and Sanofi-Aventis Have the Potential to Revolutionize the Treatment of Several Neurologic Indications

View Now